Hunan Dongting Pharmaceutical Co., Ltd.
-
Founded in:
1997-03-26 -
Country:
China -
Address:
No. 16 Dongyan Road, Chenjiagang Community, Deshan Subdistrict Office, Changde Economic and Technological Development Zone, Hunan Province (No. 16 Dongyan Road, Deshan District, Changde City) -
Tax NO.:
914307001838043692 -
Registered Funds:
309.624852 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| 1,2,3,5/4,6-cyclohexane hexane nicotine ester |
A mild peripheral vasodilator with the pharmacological effects of niacin and inositol, it has lipid-lowering effects; the vasodilator effect is mild and long-lasting, without the side effects of niacin flushing and stomach discomfort; it selectively dilates blood vessels in diseased areas and areas sensitive to cold stimulation; it has the effects of dissolving blood clots, anti-coagulation, anti-fatty liver, and reducing capillary fragility.
More
A mild peripheral vasodilator with the pharmacological effects of niacin and inositol, it has lipid-lowering effects; the vasodilator effect is mild and long-lasting, without the side effects of niacin flushing and stomach discomfort; it selectively dilates blood vessels in diseased areas and areas sensitive to cold stimulation; it has the effects of dissolving blood clots, anti-coagulation, anti-fatty liver, and reducing capillary fragility. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Escitalopram oxalate |
Escitalopram is the mono-S-enantiomer of the dicyclic hydrogenated phthalide derivative citalopram. Its antidepressant effect may be related to inhibiting the reuptake of 5-HT by central nervous system neurons, thereby enhancing the function of central serotonergic nerves. It is a highly selective 5-HT reuptake inhibitor (SSRI) with little effect on the reuptake of norepinephrine and dopamine. Escitalopram has no affinity or only low affinity for multiple receptors, and has no affinity or only low affinity for Na, K, Cl-, and Ca2+ channels.
More
Escitalopram is the mono-S-enantiomer of the dicyclic hydrogenated phthalide derivative citalopram. Its antidepressant effect may be related to inhibiting the reuptake of 5-HT by central nervous system neurons, thereby enhancing the function of central serotonergic nerves. It is a highly selective 5-HT reuptake inhibitor (SSRI) with little effect on the reuptake of norepinephrine and dopamine. Escitalopram has no affinity or only low affinity for multiple receptors, and has no affinity or only low affinity for Na, K, Cl-, and Ca2+ channels. |
219861-08-2 | 63 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Quetiapine fumarate |
This product is a new type of antipsychotic drug, which is an antagonist of multiple neurotransmitter receptors in the brain. Its antipsychotic mechanism may be mainly to block central dopamine D2 receptors and 5-HT2 receptors. It also has a blocking effect on histamine H1 and adrenaline ?1 receptors, and has no affinity for muscarinic and benzodiazepine receptors.
More
This product is a new type of antipsychotic drug, which is an antagonist of multiple neurotransmitter receptors in the brain. Its antipsychotic mechanism may be mainly to block central dopamine D2 receptors and 5-HT2 receptors. It also has a blocking effect on histamine H1 and adrenaline ?1 receptors, and has no affinity for muscarinic and benzodiazepine receptors. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Quetiapine fumarate |
A new antipsychotic drug that is an antagonist of multiple neurotransmitter receptors in the brain. It may exert its anti-schizophrenia effect by antagonizing central D2 receptors and 5-HT2 receptors. Antagonism of other receptors mediates other pharmacological effects of quetiapine; for example, antagonism of histamine H1 receptors and adrenergic a1 receptors can lead to drowsiness and orthostatic hypotension. Quetiapine has almost no affinity for cholinergic M receptors and benzodiazepine receptors (JC50% 5000nM).
More
A new antipsychotic drug that is an antagonist of multiple neurotransmitter receptors in the brain. It may exert its anti-schizophrenia effect by antagonizing central D2 receptors and 5-HT2 receptors. Antagonism of other receptors mediates other pharmacological effects of quetiapine; for example, antagonism of histamine H1 receptors and adrenergic a1 receptors can lead to drowsiness and orthostatic hypotension. Quetiapine has almost no affinity for cholinergic M receptors and benzodiazepine receptors (JC50% 5000nM). |
111974-72-2 | 112 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Quetiapine fumarate |
It is an antagonist of multiple neurotransmitter receptors in the brain. Its antipsychotic mechanism may be mainly to block central dopamine D2 receptors and 5-HT2 receptors. It also has a blocking effect on histamine H1 and adrenaline (1 receptors, and has no affinity for muscarinic and benzodiazepine receptors.
More
It is an antagonist of multiple neurotransmitter receptors in the brain. Its antipsychotic mechanism may be mainly to block central dopamine D2 receptors and 5-HT2 receptors. It also has a blocking effect on histamine H1 and adrenaline (1 receptors, and has no affinity for muscarinic and benzodiazepine receptors. |
0 |